Slides
Page 1
H & G adding life to years The Specialist in Cancer Care HEALTHCARE GLOBAL ENTERPRISES LIMITED Q1 FY2027 Results Presentation August 6 , 2026
Page 2
www.hcgoncology.com w w w . h c g o n c o l o g y. c o m Safe Harbor This presentation and its contents are confidential and are not for release, publication or distribution, in whole or in part, directly or indirectly, in or into or from the United States of America, Canada, Australia, Japan or any jurisdiction where such distribution is unlawful . This presentation has been prepared by HealthCare Global Enterprises Limited (the "Company") . These materials are not for publication or distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia) . These materials are not an offer of securities for sale into the United States, Canada or Japan or any other jurisdiction . Any securities of the Company have not been and will not be registered under the U.S. Securities Act of 1933 , as amended, and may not be offered or sold in the United States, except pursuant to an applicable exemption from registration . No public offering of any securities of the Company is being made in the United States . The information contained in this presentation is for information purposes only and does not constitute or form part of an offer or invitation for sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities, nor shall it or any part of it form the basis of or be relied on in connection with any contract, commitment or investment decision in relation thereto in India, the United States or any other jurisdiction . No person accepts any liability whatsoever for any loss howsoever arising from the use of this document or of its contents or otherwise arising in connection therewith . The information set out herein may be subject to updating, completion, revision, verification and amendment without notice and such information may change materially . Financial information contained in this presentation has been derived from the restated consolidated and standalone financial statements of the Company and have been rounded off to the next integer, except percentages which have been rounded off to one decimal point . This presentation contains certain "forward looking statements" . Forward‐looking statements are based on certain assumptions and expectations of future events . Actual future performance, outcomes and results may differ materially from those expressed in forward‐looking statements as a result of a number of risks, uncertainties and assumptions . Although the Company believes that such forward‐looking statements are based on reasonable assumptions, it can give no assurance that such expectations will be met . Neither the Company nor any of its advisors or representatives assumes any responsibility to update forward -looking statements or to adapt them to future events or developments . This presentation includes certain industry data and projections that have been obtained from industry publications and surveys . Industry publications and surveys and forecasts generally state that the information contained therein has been obtained from sources believed to be reliable, but there is no assurance that the information is accurate or complete . Neither the Company nor any of its advisors or representatives have independently verified any of the data from third -party sources or ascertained the underlying economic assumptions relied upon therein . No representation or claim is made that the results or projections contained in this presentation will actually be achieved . All industry data and projections contained in this presentation are based on data obtained from the sources cited and involve significant elements of subjective judgment and analysis, which may or may not be correct . For the reasons mentioned above, you should not rely in any way on any of the projections contained in this presentation for any purpose . No responsibility or liability whatsoever is undertaken for the contents hereof . This presentation is based on information regarding the Company and the economic, regulatory, market and other conditions as in effect on the date hereof . It should be understood that subsequent developments may affect the information contained in this presentation, which neither the Company nor its advisors or representatives are under an obligation to update, revise or affirm . 2
Page 3
www.hcgoncology.com w w w . h c g o n c o l o g y. c o m 3 Strategic Progress Over the Past Year Executing Our Strategy | Building the Foundation for Sustainable Long-Term Value Creation Completed Strategic Exit from Milann ✓ Sharpened focus on core-oncology ✓ Enhanced management focus and execution ✓ Strengthening clinical differentiation Focus on core oncology North Bengaluru Hospital Operational ✓ 120+ beds capacity added in May 26 ✓ State-of-the-art MR-LINAC commissioned ✓ Strengthens leadership in Bengaluru market Capacity expansion Successfully Completed Rights Issue ✓ Strengthened Balance sheet ✓ Enhanced financial flexibility ✓ Well positioned to fund future growth Capital strength Management Team Strengthened ✓ Leadership team fully on-boarded ✓ Execution capability strengthened ✓ Enhanced institutional governance Leadership Bed Expansion Progressing ✓ Brownfield expansion in high potential centers ✓ Unlocking embedded capacity across network ✓ Return focused capital investment Growth pipeline visibility Key Initiatives Underway ✓ Cost optimization ✓ Driving productivity improvements ✓ Enhancing patient experience Operational excellence
Page 4
www.hcgoncology.com w w w . h c g o n c o l o g y. c o m 4 Q1 FY27: Performance Update Q1 FY27: Performance Update 6,951 Mn 13% y-o-y Revenue 1,339 Mn 20% y-o-y Adjusted EBITDA1 19.4% Margins 1,223 Mn 13% y-o-y Reported EBITDA 17.6% Margins 138 Mn 190% y-o-y Profit after Tax2 2.0% Margins 78,914 11% y-o-y Volume 85,943 2% y-o-y ARPP 2,855 121 Beds Addition QoQ Operational Beds 69% 189 bps y-o-y Non-Institutional Mix Financial Highlights Operational Highlights Notes: 1. Adjusted EBITDA excludes North Bangalore Loss of INR 70 Mn and EPCG -related provision of INR 45.9 Mn in Q1 FY27 and ESOP of INR 14.5 Mn and M &A-related costs of INR 25.6 Mn in Q1 FY26 2. Profit after Tax is profit attributable to the owners of the company Revenue grew 13% y-o-y, while Adjusted EBITDA grew 20% y-o-y, with margins improving to 19.4% compared to 18.2% in Q1 FY26
Page 5
www.hcgoncology.com w w w . h c g o n c o l o g y. c o m 5 HCG Key Highlights: Q1 FY27 HCG Key Highlights: Q1 FY27 HCG delivered revenue of INR 6,951 Mn in Q1FY27, reflecting ~13% YoY growth • Broad-based growth continued across clusters in Q1FY27. Revenue growth was led by volume growth of 11% y-o-y. ARPP grew by 2%, improvement driven by a favourable payor mix was partly offset by changes in case mix, including a lower contribution from high-value, low-margin therapies o South Revenue of INR 2,765 Mn (contributing 40% of revenue) delivered ~16% YoY growth ▪ Balanced growth from volume and realization. Bangalore CoE and MGCH in AP region witnessed improvement in Cash + TPA mix o West Revenue of INR 3,010 Mn (contributing 43% of revenue) delivered ~9% YoY growth. ▪ Strong revenue growth in Maharashtra region was offset by moderated growth in Gujarat region ▪ Led by increase in patient volumes (10% YoY growth). ARPP was impacted due to higher share of medical oncology and rationalization of high-value, low- margin therapies o East Revenue of INR 799 Mn (contributing 11% of revenue) grew ~22% YoY ▪ Higher patient volumes (25% YoY growth). ARPP declined 3% YoY due to case-mix changes and a higher contribution from state-government schemes • International business revenue was INR 208 Mn, grew ~9% YoY in Q1FY27, driven by stronger patient inflows for radiation oncology and PET cases • Fertility Business divested in June 26; delivered revenue of INR 169 Mn and EBITDA of INR 23 Mn in Q1 FY27 HCG delivered Adjusted EBITDA1 of INR 1,339 Mn in Q1FY27, up ~20% YoY • Adjusted EBITDA1 margin improved to 19.4% in Q1 FY27 from 18.2% in Q1 FY26, driven by continued improvement in quality of revenue • Reported EBITDA was INR 1,223 Mn impacted due to start up losses of North Bangalore facility amounting to INR 70 Mn and EPCG related provision of INR 46 Mn Key Business Developments: 1. North Bangalore Launched o Successfully commenced operations in May 2026 with 56 operational beds, potential to expand bed capacity to 120+ beds o Strong traction post launch with 550+ New Patient registrations, 300+ admission and Revenue of INR 67 million in the first quarter o MR Linac commissioned in July 2026, making the centre home to one of India's most advanced adaptive radiation therapy platforms and expected to further enhance clinical capabilities and drive patient volume 2. Total 121 operational beds added, comprising of 56 beds at North Bangalore, 26 beds at Ranchi, 19 at Borivali, 8 at Nashik, 5 at Hubli, 7 at Kenya 3. Rajkot Upgrade: Enhanced clinical capabilities with the operationalization of a new LINAC, transforming Rajkot into a Comprehensive Cancer Care (CCC) Centre 4. Robotics Expansion: Strengthened robotic surgery capabilities with the addition of new surgical robotic systems at Nashik and replacement at Bangalore CoE Note: (1) Adjusted EBITDA excludes North Bangalore Loss of INR 70 Mn and EPCG -related provision of INR 45.9 Mn in Q1 FY27 and ESOP of INR 14.5 Mn and M&A -related costs of INR 25.6 Mn in Q1 FY26
Page 6
www.hcgoncology.com w w w . h c g o n c o l o g y. c o m 6 84,147 85,943 Q1FY26 Q1FY27 1,118 1,339 Q1FY26 Q1FY27 6,132 6,951 Q1FY26 Q1FY27 Financial Highlights: Q1 FY27 Financial Highlights: Q1 FY27 Overall Revenue Adjusted EBITDA1 Volumes (excl. Fertility)2 ARPP (excl. Fertility)2 +13% 19.4%18.2%Margin (%) +20% Notes: (1) Adjusted EBITDA excludes North Bangalore Loss of INR 70 Mn and EPCG -related provision of INR 45.9 Mn in Q1 FY27 and ESOP of INR 14.5 Mn and M&A -related costs of INR 25.6 Mn in Q1 FY26 (2) HCG completed the sale of its fertility business on 29th June, 2026 71,095 78,914 Q1FY26 Q1FY27 +11% +2% 1,101 1,315 Q1FY26 Q1FY27 5,982 6,782 Q1FY26 Q1FY27 Revenue (excl. Fertility)2 Adjusted EBITDA1 (excl. Fertility)2 +13% 19.6%18.4%Margin (%) +19%
Page 7
www.hcgoncology.com w w w . h c g o n c o l o g y. c o m 7 Revenue Mix By Specialty and Payor: Q1 FY27 Notes: (1) Modality mix : Excludes fertility business (2) OP + Other services : Includes OPD consultation, diagnostics, pharmacy and IPD related supportive care treatment (3) Payor mix excludes Fertility & International Business Payor Mix : Increasing Share of Cash & TPA Business in Line with Stated Strategy Specialty Mix Trend 37% 39% 38% 39% 14% 14% 14% 14% 20% 19% 20% 21% 16% 16% 16% 15% 13% 12% 12% 11% FY25 FY26 Q1FY26 Q1FY27 Non Oncology OP + Other services Surgical Oncology Radiation Oncology Medical Oncology 38% 40% 40% 41% 25% 25% 25% 25% 3% 2% 2% 3% 34% 33% 33% 31% FY25 FY26 Q1FY26 Q1FY27 Government Medical Value Travel TPA & Corp Cash
Page 8
www.hcgoncology.com w w w . h c g o n c o l o g y. c o m 8 Region -wise Performance Update: South Q1 FY27 (1) Bed share represents Operating beds (Census + Non -Census) Gulburga Hubli Shimonga Bangalore Chennai Vizag Vijaywada Ongole # of Centres 11 Total Operating Beds ~1,300 # of LINACs 16 Q1FY27 Highlights: • Revenue increased 16% YoY to INR 2,765 million, led by Bangalore CoE and MGCH Vizag and supported by the North Bangalore facility, which commenced operations in May 2026 and contributed INR 67 million in Q1 FY27 • Volume grew 7% YoY. The Bengaluru CoE grew 14%, with growth across modalities 30,737 31,723 32,915 Q1FY26 Q4FY26 Q1FY27 +7% 77,551 82,169 84,001 Q1FY26 Q4FY26 Q1FY27 +8% 2,384 2,607 2,765 Q1FY26 Q4FY26 Q1FY27 +16%Revenue Share % Bed Share1 % Q1 FY27 40% Q1 FY27 45% Revenue (INR Mn) Overall Volumes (# of IP Patients) Overall ARPP (INR)
Page 9
www.hcgoncology.com w w w . h c g o n c o l o g y. c o m 9 Region -wise Performance Update: West Q1 FY27 (1) Bed share represents Operating beds (Census + Non -Census) Jaipur Ahmedabad Indore Baroda Bhavnagar Nashik Mumbai Nagpur Rajkot 2,752 2,865 3,010 Q1FY26 Q4FY26 Q1FY27 +9% 28,840 30,249 31,789 Q1FY26 Q4FY26 Q1FY27 +10% 95,417 94,710 94,702 Q1FY26 Q4FY26 Q1FY27 -1% Revenue Share % Bed Share1 % Q1 FY27 43% Q1 FY27 42% # of Centres 11 Total Operating Beds ~1,190+ # of LINACs 16 Q1FY27 Highlights: • Revenue increased 9% YoY to INR 3,010 million. Strong performance in Maharashtra was partly offset by slower growth in Gujarat • Volume grew 10% YoY, supported by an improved payor mix • Payor-mix benefits were offset by higher share of medical oncology volumes and focus away from high value, lower margin therapies, leaving ARPP broadly stable Revenue (INR Mn) Overall Volumes (# of IP Patients) Overall ARPP (INR)
Page 10
www.hcgoncology.com w w w . h c g o n c o l o g y. c o m 10 Region -wise Performance Update: East Q1 FY27 (1) Bed share represents Operating beds (Census + Non -Census) Ranchi Kolkata Cuttack Revenue Share % Bed Share1 % Q1 FY27 11% Q1 FY27 12% 656 699 799 Q1FY26 Q4FY26 Q1FY27 +22% 9,800 11,095 12,296 Q1FY26 Q4FY26 Q1FY27 +25% 66,968 63,018 64,983 Q1FY26 Q4FY26 Q1FY27 -3% # of Centres 3 Total Operating Beds ~340+ # of LINACs 5 Q1FY27 Highlights: • Strong revenue growth of 22% YoY, supported by healthy patient volume growth and continued market penetration • ARPP declined 3% YoY due to case-mix changes and a higher contribution from state- government schemes Revenue (INR mn) Overall Volumes (# of IP Patients) Overall ARPP (INR)
Page 11
www.hcgoncology.com w w w . h c g o n c o l o g y. c o m www.hcgoncology.com w w w . h c g o n c o l o g y. c o m 11 HCG: Growth Plans and Strategic Priorities
Page 12
www.hcgoncology.com w w w . h c g o n c o l o g y. c o m 12 Bed Addition: 1,000 beds by FY30, led by 60% brownfield expansion Greenfield Brownfield 38 No. of Operational Beds¹ 31st Mar’26 2 Linac North Bangalore, Kenya 188 Bed addition 92 Greenfield: North Bangalore 96 • North Bangalore operationalized in Q1’27 • 26 beds added at Ranchi, 19 at Borivali, 8 at Nashik, 5 at Hubli, 7 at Kenya • 18 beds to be operationalized at Bangalore CoE and 13 at Kenya FY27 2 Linac 2 Greenfield projects ~520 Bed addition ~340 Brownfield beds • Two greenfield projects in pipeline • Additional beds to be added at Suchirayu (50), Jaipur (30), Nagpur (27), HCC Ahmedabad (23) • Brownfield capacity addition at Cuttack (75), Vizag (50) FY28 & FY29 1 Linac Greenfield project ~230 Bed addition ~100 Upcoming Greenfield project ~130 Brownfield beds • One Greenfield project • ~130 brownfield beds across ~7 existing facilities to be ramped in a phased manner FY30 ~43 ~3,670 Note: 1. Operational beds are Revenue generating beds and non-census 2. Bed Capex excludes maintenance capex Capex ~INR 1,500 Mn Capex ~INR 3,000 Mn Capex ~INR 1,000 Mn 2,734 No. of LINACs FY30 P Brownfield beds ~180 Upcoming Greenfield projects
Page 13
www.hcgoncology.com w w w . h c g o n c o l o g y. c o m 13 Optimize Existing Network Enhance Patient Experience A D 1. Build best-in-class talent → improve case mix 2. Focused marketing efforts to become provider of choice across payor types 3. Scale up international business Invest in Growth C 1. Brownfield expansion across key hospitals 2. Strengthen presence in existing markets 3. Enter identified and attractive markets which fit the expansion framework Improve Network Efficiency B 1. Undertake prudent cost optimization initiatives 2. Focus on operating leverage to improve margins 3. Develop asset light adjacencies – Day care, Diagnostics etc. 1. Invest in upgrading existing infrastructure 2. Maintain leadership in medical technology 3. Leverage digital & tech to improve patient experience HCG’s Leadership Clinical Excellence Differentiator Strategic Priorities To Accelerate Long -Term Value Creation Margin Expansion Operating leverage & efficiency ROCE Improvement Disciplined capital allocation Accelerate Revenue Growth Focus on Profitable Growth
Page 14
www.hcgoncology.com w w w . h c g o n c o l o g y. c o m 14 Q1FY27 Consolidated Profit Loss Q1FY27 Consolidated Profit & Loss Profit and Loss (INR in Mn.) Q1FY27 Q1FY26 Y-o-Y Q4FY26 Revenues from Operations 6,933.9 6,118.0 6,502.9 Income from Govt. Grant 17.1 13.6 20.4 Total Revenue from Operations 6,951.0 6,131.6 13.4% 6,523.3 Cost of Goods Sold 1,788.0 1,618.7 1,767.1 Employee Cost 1,045.2 977.7 924.7 Medical Consultancy Charges 1,574.7 1,330.2 1,403.3 Other Expenses 1,320.5 1,127.1 1,177.4 Reported EBITDA 1,222.6 1,077.9 13.4% 1,250.8 Reported EBITDA Margin (%) 17.6% 17.6% - 19.2% North Bangalore losses 70.2 Na Na Na One time cost 45.9 25.6 1.5 ESOP’s - 14.5 - Adjusted EBITDA 1,338.7 1,118.0 19.7% 1,252.3 Adjusted EBITDA Margin (%) 19.4% 18.2% +121 bps 19.2% Depreciation 704.2 579.1 628.1 Other Income 121.3 68.3 130.7 EBIT 639.7 567.1 12.8% 753.4 Finance Cost 398.7 454.7 427.0 Extraordinary Items - - 319.1 Share in Profit/(loss) in JV and Associates 9.3 6.8 5.2 Profit before Tax 250.3 119.2 110% 12.5 Taxes & Non controlling interest 112.6 71.7 9.2 Profit After Tax 137.7 47.5 190% 21.7 PAT Margin (%) 2.0% 0.8% +121 bps 0.3% Adj. Profit After Tax(1) 137.7 47.3 190% 340.8 Adj. PAT Margin (%) 2.0% 0.8% +121 bps 5.2% EPS (On reported PAT) 0.92 0.34 0.15 Note: ( 1) Q4FY26 Adjusted PAT (post Non controlling interest) is normalized for goodwill impairment of fertility business (INR 319mn)
Page 15
www.hcgoncology.com w w w . h c g o n c o l o g y. c o m 15 Q1FY27 Operational Metrics Key Metrics South West East Consolidated1 Q4FY26 Q1FY27 Q4FY26 Q1FY27 Q4FY26 Q1FY27 Q4FY26 Q1FY27 Bed Capacity 1,343 1,483 1,440 1,440 333 359 3,131 3,304 Operational Beds 1,238 1,299 1,163 1,190 318 344 2,734 2,855 Census Beds2 942 991 1,066 1,093 310 334 2,333 2,440 In-Patient Volume 31,723 32,915 30,249 31,789 11,095 12,296 74,748 78,914 ARPP (INR) 82,169 84,001 94,710 94,702 63,018 64,983 85,176 85,943 Note: 1.Consolidated is including the International business (Kenya operations ) and excluding fertility business 2.Census beds comprises of Revenue generating beds including IPD/Ward beds and Chemo beds
Page 16
www.hcgoncology.com w w w . h c g o n c o l o g y. c o m 16 www.hcgoncology.com w w w . h c g o n c o l o g y. c o m 16 HCG: India’s Leading Oncology Platform
Page 17
www.hcgoncology.com w w w . h c g o n c o l o g y. c o m 17 A Unique Oncology Platform Redefining Comprehensive Cancer Care Treatment A Unique Oncology Platform Redefining Comprehensive Cancer Care Treatment Underpinned by a personalized patient-centric approach, superior technology, and industry leading medical excellency Largest oncology-focused hospital chain with a pan-India network Preferred destination for leading oncologists to deliver advanced cancer care Deploying latest medical technology Enabling doctor to deliver cancer care with precision Focused approach and Tumor Board enabling effective cancer care Marquee leadership team and experienced management 1 2 3 4 6 Note: (1) HCG in top 3 based on management estimates. (2) Excluding Chennai A leading destination for Comprehensive Cancer Care from early diagnosis and treatment to Survivorship 5
Page 18
www.hcgoncology.com w w w . h c g o n c o l o g y. c o m 18 1. Largest Pan-India Oncology Focused Hospital Chain 1. Largest Pan -India Oncology Focused Hospital Chain Number of Cities and states covered1 No. of hospitals3 Leading positions2 19 /10 16/19 26 Number of Robotic machine5 Number of LINACs4 Number of PET CTs Operation theatres3 Capacity beds3 38 11 20 105 3k+ Note: (1) Excludes Kenya; (2) HCG in top 3 based on management estimates; excludes Chennai; (3) Includes multispecialty; (4) Inc ludes Rajkot and MSR; (5) Includes #1 ortho robotic machine at Rajkot Kenya Largest Geographical Reach… …With Leading Treatment Infrastructure Jaipur Bhavnagar Nagpur Ranchi Kolkata Cuttack Vizag Ongole Vijaywada Bangalore Hubli Mumbai (2) Nashik Gulbarga Ahmedabad Baroda Shimoga Indore Rajkot Suchirayu
Page 19
www.hcgoncology.com w w w . h c g o n c o l o g y. c o m 19 2. Preferred Platform for Leading Oncology Specialists Integrated Oncology Ecosystem Focused Specialty with Scale Full time and exclusive Oncologist Integrated Medical, Surgical & Radiation Oncology teams Organ specific Oncology teams Precision Medicine with clinical protocols Preferred destination for leading oncologists to deliver advanced cancer care Oncology-specific clinical pathways Strong referral network Higher case complexity and treatment volumes Superior clinical outcomes Specialized network impact > better outcome> more referrals > higher doctor satisfaction Access to cutting-edge technologies High degree of clinical autonomy Strong research and academics ecosystem Experienced peer group Research and collaboration reinforce superior clinical outcomes Clinical Excellence and Academics 450+ Revenue generating Oncologists 38 LINAC’s 350+ robotic surgeries Total of ~12k Surgeries as of Q1’27 88% Doctor Retention Rate in FY26 1000+ Paper Published till date 30+ New Clinical Trials in FY2026
Page 20
www.hcgoncology.com w w w . h c g o n c o l o g y. c o m 20 TRACK RECORD OF BEING 1st TO LAUNCH ADVANCED TECHNOLOGY IN INDIA Introducing organ-specific working committees – gastrointestinal, head & neck, breast, etc. for better data collection & analysis to improve patient outcome State-of-the-art Equipment in each modality Cyberknife, SRS/ SBRT Genomics Radixact AI- based RIS PACS Cyclotron FFF Technology Tomotherapy - H Ethos / Adaptive Radiation D I A G N O S T I C S R A D I O T H E R A P Y M E D I C A L / S U R G I C A L O N C O L O G Y Total PET CTs : 20 Total Robots: 11 Molecular / Genomics l ab Tomotherapy Digital Mammography Versa HD Skyra Tesla 3T for MRI Radixact Automated Breast Volume Scanner True Beam Digital PET Cyber Knife Digital CT Pathology MR-LINAC Total LINACs : 38 2013 2012 2009 2006 2022 2022 2018 2016 2026 MR-LINAC1 Bone Marrow Transplant Units Holo Lens Versius Robot Da Vinci Robot Note:(1) In new North Bangalore facility operational from July’26 3. Introducing Latest Medical Technology in Cancer Care
Page 21
www.hcgoncology.com w w w . h c g o n c o l o g y. c o m 21 4. Tumor Board Approach to Deliver Customized Treatment 4. Tumor Board Approach to Deliver Customized Treatment Spearheaded by Dr. Ajai, who also heads IRC1 of 30+ oncologists for Investigator Initiated Research Studies 17+ years of nation-wide Tumor Boards held weekly Supplemented by multiple local tumor boards Case Selection Preparation Deliberation Execution ... Is Patient FocusedMulti-disciplinary Tumor Board ... ... Takes Inputs From Large Network ... Highly specialized team Patient centric End-to- end services Accuracy and reliability 250+ Oncologists participated 36K+ Cases discussed till date Tumor board Convenor Chairman Special committee Decision Making Body Leading Oncologists Radiologists/ Pathologists Clinical Experts and academicians Panelists Treating clinicians Support Specialities2 All other clinicians Participants Sources: Company information Note: 1 Institutional Research Committee, 2 Clinical Pharmacology, Genomics, Clinical Nutrition and Dietetics, Yoga, Speech & Sw allow, Dental etc.
Page 22
www.hcgoncology.com w w w . h c g o n c o l o g y. c o m 22 5. A Leading Destination for Comprehensive Cancer Care From Early Diagnosis and Treatment to Survivorship 5. A Leading Destination for Comprehensive Cancer Care From Early Diagnosis and Treatment to Survivorship Genomics and Molecular diagnostics Digital PET Medical Oncology and Haemato- Oncology Radiation Oncology Surgical Oncology Molecular Imaging and Theranostics Preventive Oncology Psychological support Preventive Oncology Diagnostics Treatment Post Care Digital PET Digital Pathology Preventive Oncology Physical Examination Laboratory Tests Home Health Services Genomics CTC1 detection Patient Care Home Health Services Nutrition Rehab Genetic Counselling Endocrine Therapy Bone Marrow Transplant Pediatric Oncology Organ preservation & Reconstructive surgery Liver Transplant Psycho- oncology Immunotherapy Targeted Drug Therapy Iodine Therapy Robotic Surgery Radiation Chemotherapy Actinium and Lutetium therapy Psychological Support Preventive Oncology Note: (1) Circulating Tumor Cells
Page 23
www.hcgoncology.com w w w . h c g o n c o l o g y. c o m 23 6. Experienced Board of Directors 6. Experienced Board of Directors Dr. BS Ajai Kumar Founder and Non-Executive Chairman Visionary and key driving force of HCG, with an aim to make advanced cancer care accessible Dr Manish Mattoo Executive Director and CEO Seasoned healthcare leader with 20+ years of clinical & business expertise driving healthcare management Akshay Tanna Non-Executive Director Partner at KKR with 20+ years of investing and finance experience. Board member at JB Pharma, BMH, Healthium, Avendus, etc. Simrun Mehta Non-Executive Director Managing Director at KKR, serving on Boards of Vini Cosmetics, Lighthouse Learning, Avendus, BMH etc. Anjali Ajaikumar Rossi Non-Executive Director Social entrepreneur with over 15 years in healthcare; focused on quality and strategy Geeta Mathur Non-Executive Independent Director Experienced finance professional, serving on Boards of Ashok Leyland, Info Edge, JSW One, IIFL group etc. Rajagopalan Raghavan Non-Executive Independent Director 30+ years of leadership experience. Currently serving as Chief Human Resource Officer at CoreStack Pradip Kanakia Non-Executive Independent Director 36+ years in audit and governance and have held leadership positions in Price Waterhouse, KPMG. On the Board of JM Financial, Britannia Industries, ICRA Limited etc. Rajiv Maliwal Non-Executive Independent Director Founder of Sabre Partners with 30+ years of investment experience. Board member at Wellspring Healthcare, Monepeak Fintech etc. Bijou Kurien Non-Executive Independent Director Consumer industry leader with 40+ years experience across Titan & Reliance Retail. Board member & advisor to multiple companies
Page 24
www.hcgoncology.com w w w . h c g o n c o l o g y. c o m 24 HCG Shareholding Pattern and Key Shareholders * All logos are for representation purpose only and copyright belong to the respective owners Promoters 64% Domestic Institutional Investors 19% Foreign Institutional Investors 3% Public 14% Top Institutional Investors as on 30th June 2026 30th June, 2026
Page 25
www.hcgoncology.com w w w . h c g o n c o l o g y. c o m 25 Annexure: Definitions Key Metrics Definitions Bed Capacity Bed Capacity reflects total beds that can be accommodated in the hospitals Operational / Census Beds Operational beds comprises of Census and non-census beds Census Beds Revenue generating beds including IPD/Ward beds and Chemo beds Non-Census Beds Transient Beds including Emergency, triage, pre-op/post op etc Volume In-patient volume includes IPD volumes, Chemo cycle and Radiation volume ARPP (In INR) Revenue from Operations / In-patient Volume
Page 26
www.hcgoncology.com w w w . h c g o n c o l o g y. c o m For updates and specific queries, please visit www.hcgoncology.com or contact: HealthCare Global Enterprises Limited investors@hcgoncology.com Ravi Gothwal Head Investor Relations Ravi.gothwal@ hcgel.com Tel: +91 95996 55711 Anoop Poojari / Suraj Digawalekar CDR India anoop@cdr -india.com / suraj@cdr -india.com Tel: +91 98330 90434 / +91 98211 94418 About Us: HealthCare Global Enterprises Ltd. (HCG), headquartered in Bengaluru, is the largest provider of cancer care in India. Through its network of 26 hospitals across India and Kenya, HCG has brought advanced cancer care to the doorstep of millions of people. HCG’s comprehensive cancer centers provide expertise and advanced technologies for the effective diagnosis and treatment of cancer under one roof. CIN: L15200KA1998PLC023489 26
Page 27
www.hcgoncology.com w w w . h c g o n c o l o g y. c o m THANK YOU